HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924
Paul Haluska(Mayo Clinic in Arizona), Charles Erlichman(Roswell Park Comprehensive Cancer Center)
Cited by 101
Related Papers
Up-regulation of Heat Shock Protein 27 Induces Resistance to 17-Allylamino-Demethoxygeldanamycin through a Glutathione-Mediated Mechanism
|Cancer Research|2006|156
P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
|Cancer Research|2008|75
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast Cancer
|Clinical Cancer Research|2017|74
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
|npj Breast Cancer|2021|29